JP6219841B2 - 放射性構成物およびそれらの治療的使用方法 - Google Patents

放射性構成物およびそれらの治療的使用方法 Download PDF

Info

Publication number
JP6219841B2
JP6219841B2 JP2014548954A JP2014548954A JP6219841B2 JP 6219841 B2 JP6219841 B2 JP 6219841B2 JP 2014548954 A JP2014548954 A JP 2014548954A JP 2014548954 A JP2014548954 A JP 2014548954A JP 6219841 B2 JP6219841 B2 JP 6219841B2
Authority
JP
Japan
Prior art keywords
formula
equal
radioactive
composition
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014548954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510496A5 (enExample
JP2015510496A (ja
Inventor
エー．ウィルソン デイビッド
エー．ウィルソン デイビッド
フランク アール．キース
フランク アール．キース
サイモン ジェイミー
サイモン ジェイミー
ケー．クランプ ドゥルース
ケー．クランプ ドゥルース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IsoTherapeutics Group LLC
Original Assignee
IsoTherapeutics Group LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IsoTherapeutics Group LLC filed Critical IsoTherapeutics Group LLC
Publication of JP2015510496A publication Critical patent/JP2015510496A/ja
Publication of JP2015510496A5 publication Critical patent/JP2015510496A5/ja
Application granted granted Critical
Publication of JP6219841B2 publication Critical patent/JP6219841B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
JP2014548954A 2011-12-21 2012-12-21 放射性構成物およびそれらの治療的使用方法 Active JP6219841B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161578630P 2011-12-21 2011-12-21
US61/578,630 2011-12-21
US201261606734P 2012-03-05 2012-03-05
US61/606,734 2012-03-05
PCT/US2012/071256 WO2013096776A2 (en) 2011-12-21 2012-12-21 Radioactive compositions and methods for their therapeutic use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017047326A Division JP6356854B2 (ja) 2011-12-21 2017-03-13 放射性構成物およびそれらの治療的使用方法

Publications (3)

Publication Number Publication Date
JP2015510496A JP2015510496A (ja) 2015-04-09
JP2015510496A5 JP2015510496A5 (enExample) 2016-04-07
JP6219841B2 true JP6219841B2 (ja) 2017-10-25

Family

ID=48669706

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014548954A Active JP6219841B2 (ja) 2011-12-21 2012-12-21 放射性構成物およびそれらの治療的使用方法
JP2017047326A Active JP6356854B2 (ja) 2011-12-21 2017-03-13 放射性構成物およびそれらの治療的使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017047326A Active JP6356854B2 (ja) 2011-12-21 2017-03-13 放射性構成物およびそれらの治療的使用方法

Country Status (8)

Country Link
US (3) US9687574B2 (enExample)
EP (1) EP2793955B1 (enExample)
JP (2) JP6219841B2 (enExample)
KR (2) KR102006599B1 (enExample)
AU (1) AU2012358364B2 (enExample)
CA (1) CA2859971C (enExample)
ES (1) ES2671622T3 (enExample)
WO (1) WO2013096776A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017149722A (ja) * 2011-12-21 2017-08-31 アイソセラピューティクス グループ リミティド ライアビリティー カンパニーＩｓｏＴｈｅｒａｐｅｕｔｉｃｓ Ｇｒｏｕｐ ＬＬＣ 放射性構成物およびそれらの治療的使用方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160037877A (ko) * 2013-06-05 2016-04-06 알-내브, 엘엘씨 Ｔｉｎ―１１７ｍ으로 면역성, 염증성 및 퇴행성 관절염증의 치료 방법
US20210402012A1 (en) 2018-12-14 2021-12-30 Quirem Medical B.V. Particle comprising lanthanide hydroxide
US20220305150A1 (en) * 2019-06-18 2022-09-29 Serene, Llc Novel tin-117m colloid formulation with the ability to distinguish it from existing tin-117m colloid formulations
CN115279456A (zh) 2020-01-28 2022-11-01 反射医疗公司 放射性核素与外部束放疗的联合优化

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4533541A (en) 1983-08-25 1985-08-06 The United States Of America As Represented By The United States Department Of Energy Tin-117m-labeled stannic (Sn4+) chelates
JPH02501062A (ja) * 1986-11-17 1990-04-12 クラークソン ユニバーシティ 希土類酸化物の均一なコロイド状粒子の合成方法
US4906450A (en) 1987-03-26 1990-03-06 Ephraim Lieberman Treatment of arthritis, including rheumatoid arthritis, with the radionuclide, tin SN-121
US5045289A (en) * 1989-10-04 1991-09-03 Research Corporation Technologies, Inc. Formation of rare earth carbonates using supercritical carbon dioxide
US5320824A (en) 1989-10-12 1994-06-14 Mallinckrodt Medical, Inc. Radionuclide labelled particles useful for radiation synovectomy
US5061476A (en) 1989-12-27 1991-10-29 The Dow Chemical Company Radiolabeled colloid compositions and method for preparing same
US5137709A (en) * 1991-02-15 1992-08-11 The Dow Chemical Company Layered mixed metal hydroxides for the stabilization of radioactive colloids
JP3122319B2 (ja) 1994-05-02 2001-01-09 アソシエーティド ユニバーシティーズ，インコーポレイティド 錫−１１７ｍ−含有放射性治療剤
DE69518769T2 (de) * 1994-07-01 2001-01-04 Sarnoff Corp., Princeton Verfahren zur herstellung kleiner phosphorpartikel
US6132642A (en) 1994-07-01 2000-10-17 Sarnoff Corporation Method of preparing small particle size phosphors
US6231832B1 (en) 1998-03-23 2001-05-15 Brookhaven Science Associates Radiopharmaceutical stannic Sn-117m chelate compositions and methods of use
US6004532A (en) 1998-06-08 1999-12-21 Brookhaven Science Associates Formulation for Tin-117m /diethylenetriaminepentaacetic acids
US7045166B2 (en) 1998-08-27 2006-05-16 Silver Barnard S Sweetener compositions containing fractions of inulin
GB0020610D0 (en) 2000-08-21 2000-10-11 Dytech Corp Ltd Uses of porous carriers
US7893223B2 (en) * 2001-07-17 2011-02-22 Bracco Imaging S.P.A. Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
US7731648B2 (en) 2001-07-25 2010-06-08 Aduro Biotech Magnetic nanoscale particle compositions, and therapeutic methods related thereto
WO2003051403A1 (en) * 2001-12-13 2003-06-26 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals
EP1572247A1 (en) * 2002-12-10 2005-09-14 University Of Miami Radioablation of hemolymphopoietic cell populations
US20070269375A1 (en) * 2003-07-24 2007-11-22 Bracco Imaging S.P.A. Stable Radiopharmaceutical Compositions and Methods for Preparation
US20060014938A1 (en) 2004-07-14 2006-01-19 Groman Ernest V Stable aqueous colloidal lanthanide oxides
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US20100196268A1 (en) * 2008-02-15 2010-08-05 Isotherapeutics Group Llc Compositions and methods for treatment of tumors by direct administration of a radioisotope
WO2009045230A1 (en) * 2007-10-05 2009-04-09 Iso Therapeutics Group Llc Compositions for treatment of tumors by direct administration of a radioisotope
US20090191126A1 (en) * 2007-11-27 2009-07-30 The Regents Of The University Of California Peptide and multivalent peptide conjugate for diagnosis and treatment of vascular plaques
WO2009073193A2 (en) * 2007-12-03 2009-06-11 The Johns Hopkins University Methods of synthesis and use of chemospheres
JP2011518198A (ja) 2008-04-24 2011-06-23 ジ オーストラリアン ナショナル ユニバーシティー 放射性標識合成ポリマーのための方法
US20120316633A1 (en) * 2011-06-07 2012-12-13 Boston Scientific Scimed, Inc. Durable Stent Drug Eluting Coating
KR102006599B1 (ko) * 2011-12-21 2019-08-01 아이소테라퓨틱스 그룹 엘엘씨 방사성 조성물 및 그의 치료적 사용 방법
MY150861A (en) * 2012-07-18 2014-03-06 Univ Malaya Neutron activated 153sm labelled microspheres

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017149722A (ja) * 2011-12-21 2017-08-31 アイソセラピューティクス グループ リミティド ライアビリティー カンパニーＩｓｏＴｈｅｒａｐｅｕｔｉｃｓ Ｇｒｏｕｐ ＬＬＣ 放射性構成物およびそれらの治療的使用方法

Also Published As

Publication number Publication date
US9687574B2 (en) 2017-06-27
EP2793955A4 (en) 2016-01-06
US20200155716A1 (en) 2020-05-21
KR102006599B1 (ko) 2019-08-01
US10583211B2 (en) 2020-03-10
US20150023869A1 (en) 2015-01-22
KR101973830B1 (ko) 2019-04-29
US10918746B2 (en) 2021-02-16
AU2012358364A1 (en) 2014-08-07
KR20140105016A (ko) 2014-08-29
JP6356854B2 (ja) 2018-07-11
KR20190047101A (ko) 2019-05-07
AU2012358364B2 (en) 2017-08-10
WO2013096776A3 (en) 2015-01-08
CA2859971C (en) 2020-08-04
US20170258949A1 (en) 2017-09-14
CA2859971A1 (en) 2013-06-27
ES2671622T3 (es) 2018-06-07
WO2013096776A2 (en) 2013-06-27
JP2017149722A (ja) 2017-08-31
JP2015510496A (ja) 2015-04-09
EP2793955A2 (en) 2014-10-29
EP2793955B1 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
US10918746B2 (en) Radioactive compositions and methods for their therapeutic use
Klaassen et al. The various therapeutic applications of the medical isotope holmium-166: a narrative review
ES2268888T3 (es) El uso de radio-223 para dirigirse a tejidos calcificados para paliacion del dolor y terapia de cancer oseo.
JP5219325B2 (ja) 骨標的錯体
US11369681B2 (en) Radio-wave responsive doped nanoparticles for image-guided therapeutics
Katti et al. Prostate tumor therapy advances in nuclear medicine: green nanotechnology toward the design of tumor specific radioactive gold nanoparticles
JP2010516705A (ja) 温熱療法におけるサセプタとその使用法
EA020542B1 (ru) Альфа-излучающие частицы гидроксиапатита
Hassfjell et al. 212Bi-DOTMP: an alpha particle emitting bone-seeking agent for targeted radiotherapy
JP2010540627A (ja) 放射性同位体の直接投与による腫瘍治療のための組成物
CN107073142A (zh) 用于放射成像和疗法的磷酸锶微粒
TW508243B (en) Novel radiopharmaceutical compositions and matrices and uses thereof
WO2011149844A1 (en) Delivery of high dose therapeutic radioisotopes to bone
US20120251442A1 (en) Methods for Treatment of Tumors by Direct Administration of a Radioisotope
Tishchenko et al. Radiopharmaceuticals based on polyaminophosphonic acids labeled with α−, β−, and γ-emitting radionuclides
JP2002514159A (ja) 新規放射性医薬組成物とマトリクスおよびそれらの使用
KR101165518B1 (ko) 알파-방출 히드록시아파타이트 입자
JP5956533B2 (ja) 放射ターゲット薬物調製用キット及び放射ターゲット薬物の調製方法及び用途
Ocak et al. Radiopharmaceuticals for Radionuclide Therapy
AU2003203953A1 (en) Combination Therapy for Treatment of Neoplasia

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170928

R150 Certificate of patent or registration of utility model

Ref document number: 6219841

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250